Company intelligence / Profile preview

Millendo Therapeutics

Ann Arbor, Michigan, USAmillendo.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Millendo Therapeutics was a clinical-stage biopharmaceutical company focused on developing novel treatments for endocrine diseases with significant unmet medical need. Its pipeline included nevanimibe for CAH, MLE4901/301 for PCOS and menopausal hot flashes, and livoletide for PWS. The company faced multiple setbacks including failed trials and ultimately discontinued its lead program livoletide after negative results. In June of 2021, Millendo merged with Tempest Therapeutics; the combined entity now operates as Tempest focusing on oncology[4][6][7].

Therapeutic areas: Women's HealthEndocrinologyRare Diseases
Modalities: small molecules (e.g., nevanimibe, MLE4901/301)peptides (e.g., livoletide)
Industry: Biotech

Beyond the preview

Go deeper on Millendo Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Millendo Therapeutics.